If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
Priced IPO
Solaredge Technologies, Inc. (SEDG)
The Marygold Companies (MGLD)
Blue Water Vaccines (BWV)
Meihua International Medical Technologies (MHUA)
Smart for Life (SMFL)
Vivakor (VIVK)
TC BioPharm Holdings (TCBP)
Direct Digital Holdings, Llc (DRCT)
Modiv (MDV)
Sky Technologies (SKYX)
Modular Medical (MODD)
HeartCore Enterprises (HTCR)
Arcellx, Inc. (ACLX)
Silver Spike Investment Corp. (SSIC)
Maris-Tech Ltd. (MTEK)
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
More companies

Biofrontera (BFRI)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

They are a U.S.-based biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, in particular, diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Their licensed products focus on the treatment of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer. They also market a topical antibiotic for treatment of impetigo, a bacterial skin infection. Their principal product is Ameluz®, which is a prescription drug approved for use in combination with their licensor’s medical device, which has been approved by the U.S. Food and Drug Administration (the “FDA”), the BF-RhodoLED® lamp, for photodynamic therapy, or PDT, (when used together, “Ameluz® PDT”) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. They are currently selling Ameluz® for this indication in the U.S. under an exclusive amended and restated license and supply agreement, or Ameluz LSA, by and among them, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH dated as of June 16, 2021. See “Busines--Commercial Partners and Agreements--Biofrontera Pharma and Biofrontera Bioscience” in this prospectus for more information. Under the Ameluz LSA, they hold the exclusive license to sell Ameluz® and the BF-RhodoLED® lamp for all indications currently approved by the FDA as well as all future FDA-approved indications. As further described below, under the Ameluz LSA, further extensions of the approved indications for Ameluz® photodynamic therapy in the United States are anticipated.
Pharmaceutical Preparations
Employees Founded
64 2015


Address: 120 Presidential Way, Suite 330 Woburn, Ma 01801

Telephone: 781-245-1325

Web page:

IPO information

First Trade Date 10/29/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 3
Shares Revised (MM) 3.6
Expected offer amount (MM) $25
Realized offer amount(MM) $18

Financial Data (last reporting year)

Market Cap (MM) $66.0
Revenues (MM) $22.42
Net Income (Loss) (MM) $-10.37


What do you think will happen with the BFRI share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Roth Capital

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Roth Capital/ The Benchmark Company

Sector: Healthcare

Tweets about $BFRI

Tweets volume:

RT volume:


Google Trends Stats